Home>Topics>Stocks>Exelixis

Exelixis EXEL

  1. All
  2. Commentary
  3. Headlines
    1. Exelixis' 4Q Results In Line; Key Phase III Results Expected in 2Q

      Commentary

      Thu, 26 Feb 2015

      quarter results, we are increasing our fair value estimate for Exelixis to $2.70 per share from $2.10 due primarily to a lowering ..... clinical trial and the company's dwindling cash reserves, Exelixis faces an increasingly uncertain future. Cometriq revenue for

    2. REFILE-UPDATE 1-Tesco names former Exel CEO John Allan as chairman

      Headlines

      Tue, 17 Feb 2015

      LONDON, Feb 17 (Reuters) - Tesco, Britain's biggest retailer, has named John Allan as its new chairman, succeeding Richard Broadbent who said in October he would step down in the wake of the supermarket's 263 million pounds ($403 million) profit overstatement.

    3. Exelixis 3Q Results as Expected; Maintaining FVE

      Commentary

      Wed, 5 Nov 2014

      Exelixis reported in-line third-quarter results and positive Phase II data for Cometriq ..... the clinical trial and the company’s rapidly dwindling cash reserves, Exelixis faces an uncertain future. Cometriq revenue for the quarter was $6.3

    4. Cobimetinib Combo Results are Positive, but Melanoma Landscape Is Becoming More Challenging

      Commentary

      Mon, 29 Sep 2014

      Exelixis and partner Roche reported positive detailed results for their Phase III study of MEK inhibitor cobimetinib in combination with

    5. UPDATE 1-Roche, GSK melanoma pill combinations look similar in showdown

      Headlines

      Mon, 29 Sep 2014

      * Shares in Roche's biotech partner Exelixis jump 20 pct (Adds Exelixis share price jump, more on treatment debate)

    6. Exelixis Fails in Key Prostate Cancer Trial; Dramatically Lowering Fair Value Estimate

      Commentary

      Tue, 2 Sep 2014

      Exelixis announced Monday that its key Phase III COMET-1 trial in men with metastatic ..... statistically significant (p value of 0.21). Based on the trial result, Exelixis plans to halt its clinical program in prostate cancer and reduce its workforce

    7. Exelixis' 2Q Results In Line; Phase III Prostate Cancer Results Later This Year Remain Key Driver

      Commentary

      Fri, 1 Aug 2014

      Exelixis reported second-quarter results that were generally consistent with our ..... year and represent the major catalysts for the firm. During the quarter, Exelixis and partner Roche announced positive top-line results for their Phase

    8. Positive Phase III Results With Roche-Partnered Program; Cometriq Trials Remain Key Driver

      Commentary

      Mon, 14 Jul 2014

      Exelixis and partner Roche have announced positive top-line results for their Phase ..... 50 per share fair value estimate and no-moat, stable trend rating for Exelixis , as we continue to await the more important Phase III results for Cometriq

    9. EXEL - Coming back or a dog?

      Commentary

      Thu, 10 Jul 2014

      Not much news on this one lately, depsite a big drop following Morningstar's latest reaffirmation.  Still a Monringstar 5-star, but lots of shorts and mixed thoughts across traders.  Just bought in at 3 and a quarter, so we'll see.  Speculative at best at this point.  

    10. Exelixis 1Q Results as Expected; Phase III Prostate Cancer Results in 2014 Remain Key Driver

      Commentary

      Fri, 2 May 2014

      Exelixis reported first-quarter results that were generally consistent with our ..... this year and represent the major catalysts for the firm. In addition, Exelixis ’ partnered asset with Roche, MEK inhibitor GDC-0973 (in combination

    « Prev12345Next »
    Content Partners